Menarini

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Menarini, Multimedia, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, CDX, Neoplasm, Patient, Safety, Intelligence, Medical imaging

This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.

Key Points: 
  • This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.
  • Insilico presented data on the molecule at the San Antonio Breast Cancer Symposium in early December.
  • Currently, endocrine therapy in combination with CDK4/6 inhibitors is the standard treatment for ER+/HER2- breast cancer patients with advanced or metastatic disease.

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Diabetes, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Medicine, Observation, Research, Safety, Therapy, Toxicity, Cohort, University, Everolimus, Learning, Brain, Patient, Ribociclib, Division, Pharmacokinetics, Hematology, Neutropenia, Diarrhea, Nausea, Cancer, Financial toxicity, Menarini, Traffic barrier, Pharmaceutical industry, MD

Both the ELEVATE and ELECTRA studies were designed with the objective to overcome different resistance mechanisms and enhance patient outcomes with combination treatment options.

Key Points: 
  • Both the ELEVATE and ELECTRA studies were designed with the objective to overcome different resistance mechanisms and enhance patient outcomes with combination treatment options.
  • Data was presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • The ELEVATE study is evaluating elacestrant in combination with inhibitors of the PI3K/AKT/mTOR pathway (everolimus and alpelisib) and cell-cycle pathway inhibitors (palbociclib, ribociclib, and abemaciclib).
  • Additional cohorts are currently under evaluation to assess pharmacokinetics (PK) and determine the recommended phase 2 dose (RP2D) for each combination.

Global Premature Ejaculation Therapeutics Market Insights Report 2024-2029 Featuring Prominent Vendors - Plethora Solutions, Pfizer, Eli Lilly and Co, GSK, Menarini - ResearchAndMarkets.com

Retrieved on: 
Monday, December 11, 2023
Health, Pharmaceutical, Sale, Prevalence, Therapy, Ageing, GSK plc, Premature ejaculation, Route of administration, GSK, ROA, Eli Lilly and Company, Growth, Menarini, Administration, Physician, Selective serotonin reuptake inhibitor, Pharmaceutical industry, Generic drug, Pfizer

This report offers market size & forecast data for the global premature ejaculation therapeutics market.

Key Points: 
  • This report offers market size & forecast data for the global premature ejaculation therapeutics market.
  • This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029.
  • Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market.

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

Retrieved on: 
Friday, December 8, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, DSM-IV codes, Vomiting, Woman, Safety, CDK, Potassium, Therapy, Letrozole, Progression-free survival, Back pain, Fulvestrant, Abdominal pain, Doctor of Science, Headache, Risk, Liver, Disease, Cholesterol, PIK3CA, Constipation, Fatigue, Indigestion, Anastrozole, Patient, Multimedia, PFS, Metastasis, MD Anderson Cancer Center, ESR1, FDA, MBC, Neoplasm, Creatinine, Standard of care, Diarrhea, MD, Nausea, Cancer, Trial of the century, Death, Exemestane, Menarini, Anemia, SOC, TP53, Knowledge, Arthralgia, HIV disease progression rates, Triglyceride, Medical imaging, Pharmaceutical industry

This data is being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.

Key Points: 
  • This data is being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or mBC.
  • “At Menarini Stemline our goal is to provide transformational treatments to help extend and improve the lives of people living with cancer.
  • See here for details of the Menarini Group/Stemline Therapeutics' full range of presentations at SABCS 2023.

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, November 20, 2023
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Woman, Safety, Food, Therapy, European Commission, ASH, HIV disease progression rates, Civil service commission, Patient, Multimedia, ESR1, FDA, MBC, Menarini, Bone marrow, Cancer, Survival, Biomarker, Society, Mutation, BPDCN, Pharmaceutical industry, Dietary supplement, Medical imaging

In September 2023 , ORSERDU was approved by the European Commission.

Key Points: 
  • In September 2023 , ORSERDU was approved by the European Commission.
  • Updated data, including a spotlight discussion on additional biomarker and clinical subgroup analyses from the Phase 3 EMERALD trial, along with new safety updates evaluating elacestrant in multiple combination settings, will be presented at the San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • Updated data, including an oral presentation of updated real-world results in treatment-naïve patients with BPDCN demonstrating durable outcomes and a manageable safety profile leading to prolonged survival, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 9-12, 2023.
  • “The breadth of data on our novel oncology therapies, spanning solid tumors and hematologic malignancies, underscore our commitment to addressing significant unmet medical needs in difficult-to-treat cancers,” said Elcin Barker Ergun, CEO of the Menarini Group.

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 11, 2023
Medicine, Observation, Research, Safety, CDK, Therapy, Toxicity, Cohort, University, Disease, Everolimus, Learning, Brain, Patient, Ribociclib, Division, Pharmacokinetics, Hematology, Neutropenia, Menarini, Diarrhea, Nausea, Cancer, Toxic leukoencephalopathy, Traffic barrier, Pharmaceutical industry, MD

Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.

Key Points: 
  • Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.
  • Both the ELEVATE and ELECTRA studies were designed with the objective to overcome different resistance mechanisms and enhance patient outcomes with combination treatment options.
  • Data was presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • "We look forward to learning more about ORSERDU's role in combination settings and its potential across the spectrum of metastatic breast cancer."

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 11, 2023
Medicine, Observation, Research, Safety, CDK, Therapy, Toxicity, Cohort, University, Disease, Everolimus, Learning, Brain, Patient, Ribociclib, Division, Pharmacokinetics, Hematology, Neutropenia, Menarini, Diarrhea, Nausea, Cancer, Toxic leukoencephalopathy, Traffic barrier, Pharmaceutical industry, MD

Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.

Key Points: 
  • Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.
  • Both the ELEVATE and ELECTRA studies were designed with the objective to overcome different resistance mechanisms and enhance patient outcomes with combination treatment options.
  • Data was presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • "We look forward to learning more about ORSERDU's role in combination settings and its potential across the spectrum of metastatic breast cancer."

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Retrieved on: 
Wednesday, November 8, 2023
Research, Genetics, Clinical Trials, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, European Organisation for Research and Treatment of Cancer, Patient, III, SERD, Treatment, EORTC, Menarini, NTRA, Circulating tumor DNA, MRD, Recurrence, Breast cancer, Neoplasm, Death, DNA, Medical imaging, Natera, Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).
  • This international, multi-center, randomized, phase III clinical trial is being conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group in collaboration with Natera and Menarini Group (Menarini), a leading international pharmaceutical and diagnostics company.
  • “We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the TREAT ctDNA trial.
  • “Collaborations with leading clinical trial organizations like EORTC are needed as we seek to demonstrate the power of treatment on molecular recurrence across cancer indications.